Biogen and Sage complete FDA rolling submission of depression drug
Biogen and its partner Sage Therapeutics have now completed the rolling submission process for their depression drug zuranolon at the US Food and Drug Administration.
by christopher due karlsson, translated by catherine brett
US-based Biogen and its partner Sage Therapeutics have completed their rolling submission of depression drug zuranolon to the FDA, Biogen reveals in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Extra data boosts Lundbeck's agitation case
For subscribers
